{"id":"W4396599772","doi":"10.1158/1538-7445.sabcs23-ps12-08","title":"Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Fulvestrant; Atezolizumab; Medicine; Oncology; Internal medicine; Cancer; Interim analysis; Breast cancer; Metastatic breast cancer; Disease; Estrogen receptor; Clinical trial; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003933934,0.0003243323,0.001067036,0.001310321,0.00008484961,0.00003055115,0.0001656153,0.00004279084,0.0006640038],"category_scores_gemma":[0.00003987535,0.0002551914,0.0001892846,0.002400803,0.0003782999,0.0002179131,0.0001032372,0.0003512872,0.000002737235],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00131315,"about_ca_system_score_gemma":0.0007232288,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007162878,"about_ca_topic_score_gemma":0.0007351937,"domain_scores_codex":[0.9968466,0.0002157552,0.0007304127,0.0007226726,0.0009422113,0.0005423756],"domain_scores_gemma":[0.9983277,0.0001994278,0.000149058,0.0004764102,0.0004763196,0.0003711234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.09432938,0.02586335,0.1375828,0.002036572,0.02414105,0.0009510635,0.03087346,0.001038052,0.07925505,0.00004264519,0.0001814452,0.6037052],"study_design_scores_gemma":[0.03083465,0.0108151,0.9406905,0.001639498,0.003829236,0.000007563603,0.004573953,0.0009811471,0.005958664,0.00005745816,0.0001969942,0.0004152151],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817873,0.01165913,0.00001138219,0.0004670576,0.00007971484,0.002022135,0.003926032,0.00002819529,0.00001910246],"genre_scores_gemma":[0.9963484,0.002322857,0.00003589187,0.00001370655,0.00005163495,0.0009162265,0.000140541,0.00005224615,0.0001185298],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8031077,"threshold_uncertainty_score":0.99999,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06473927860091323,"score_gpt":0.4428545749237581,"score_spread":0.3781152963228449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}